Quick answers
- What is Meropenem used for?
- The FDA-approved label (Meropenem and Sodium Chloride, B. Braun Medical Inc., August 5, 2025) says: “Meropenem for Injection and Sodium Chloride Injection is a penem antibacterial indicated for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older requiring the full adult dose only). Complicated intra-abdominal infections (adult patients and pediatric patients 3 months of age and older requiring the full adult dose only). …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Meropenem have a boxed warning?
- No. None of the 24 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Meropenem?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Meropenem been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Meropenem?
- 18 companies list prescription products of Meropenem in the FDA NDC Directory, including Fresenius Kabi USA, LLC, WG Critical Care, LLC and Hospira, Inc..
What Meropenem is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Meropenem for Injection and Sodium Chloride Injection is a penem antibacterial indicated for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older requiring the full adult dose only). Complicated intra-abdominal infections (adult patients and pediatric patients 3 months of age and older requiring the full adult dose only). …
— FDA label: Meropenem and Sodium Chloride, B. Braun Medical Inc., effective August 5, 2025. Read the full label on DailyMed →
The FDA has 24 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 24 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Injection, powder, for solution · Injection · Injection, solution |
|---|---|
| Route | Intravenous |
| Prescription products | 45 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| meropenem 1 g injection, powder, for solution | Generic | $5.04 per unit |
| meropenem 1 g/20 mL injection | Generic | $5.04 per unit |
| meropenem 1 g/20 mL injection, powder, for solution | Generic | $5.04 per unit |
| meropenem 1 g/30 mL injection | Generic | $5.04 per unit |
| meropenem 1 g/30 mL injection, powder, for solution | Generic | $5.04 per unit |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Fresenius Kabi USA, LLC6 products
- WG Critical Care, LLC5 products
- Hospira, Inc.4 products
- Civica, Inc.4 products
- Hikma Pharmaceuticals USA Inc.4 products
- Brooks Steriscience Limited3 products
- Sandoz Inc2 products
- Gland Pharma Limited2 products
- Armas Pharmaceuticals Inc.2 products
- Sagent Pharmaceuticals2 products
- B. Braun Medical Inc.2 products
- Xellia Pharmaceuticals USA LLC2 products
- Eugia US LLC2 products
- BluePoint Laboratories2 products
- Savior Lifetec Corporation2 products
- Amneal Pharmaceuticals LLC2 products
- Qilu Antibiotics Pharmaceutical Co., Ltd.2 products
- Mylan Institutional LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA202106 MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | B Braun Medical | April 30, 2015 | 4, latest December 3, 2024 2024: Labeling · 2020: Labeling · 2018: Labeling |
| NDA215212 MEROPENEM | Hq Spclt Pharma | July 26, 2023 | 2, latest August 10, 2026 2026: Labeling · 2024: Labeling |
Generic approvals (9)
- ANDA091404Acs Dobfar · October 26, 2011
- ANDA205883Amneal Pharms · April 12, 2016
- ANDA206086Savior Lifetec Corp · April 19, 2016
- ANDA206141Gland · June 8, 2016
- ANDA205835Eugia Pharma · March 27, 2017
- ANDA210773Hq Spclt Pharma · August 16, 2019
- ANDA216154Brooks Steriscience · August 18, 2022
- ANDA216424Qilu · July 22, 2024
- ANDA219084Brooks Steriscience · June 23, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1722934, 1722939, 2664894 |
|---|---|
| SPL set ID of the quoted label | 3b952a55-6ef7-45c8-be21-16eefe37ec2e |
| FDA labels (SPL) | 24 |
| FDA applications | NDA202106, NDA215212, 9 ANDA |
| Active ingredients (FDA) | MEROPENEM |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Meropenem and Sodium Chloride, B. Braun Medical Inc., effective August 5, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →